1 5297 164 PROTEIN ARGININE METHYLTRANSFERASE 5 CONTRIBUTES TO PACLITAXEL-INDUCED NEUROPATHIC PAIN BY ACTIVATING TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 EPIGENETIC MODIFICATION IN DORSAL ROOT GANGLION. BACKGROUND: PACLITAXEL (PTX), WHICH IS A FIRST-LINE CHEMOTHERAPY DRUG USED TO TREAT VARIOUS TYPES OF CANCERS, EXHIBITS PERIPHERAL NEUROPATHY AS A COMMON SIDE EFFECT THAT IS DIFFICULT TO TREAT. PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT 5) IS A KEY REGULATOR OF THE CHEMOTHERAPY RESPONSE, AS CHEMOTHERAPY DRUGS INDUCE PRMT5 EXPRESSION. HOWEVER, LITTLE IS KNOWN ABOUT THE PRMT5-MEDIATED EPIGENETIC MECHANISMS INVOLVED IN PTX-INDUCED NEUROPATHIC ALLODYNIA. METHODS: SPRAGUE-DAWLEY RATS WERE INTRAPERITONEALLY GIVEN PTX TO INDUCE NEUROPATHIC PAIN. BIOCHEMICAL ANALYSES WERE CONDUCTED TO MEASURE THE PROTEIN EXPRESSION LEVELS IN THE DORSAL ROOT GANGLION (DRG) OF THE ANIMALS. THE VON FREY TEST AND HOT PLATE TEST WERE USED TO EVALUATE NOCICEPTIVE BEHAVIORS. RESULTS: PTX INCREASED THE PRMT5 (MEAN DIFFERENCE [MD]: 0.68, 95% CONFIDENCE INTERVAL [CI], 0.88-0.48; P < .001 FOR VEHICLE)-MEDIATED DEPOSITION OF HISTONE H3R2 DIMETHYL SYMMETRIC (H3R2ME2S) AT THE TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 (TRPV1) PROMOTER IN THE DRG. PRMT5-INDUCED H3R2ME2S RECRUITED WD REPEAT DOMAIN 5 (WDR5) TO INCREASE TRIMETHYLATION OF LYSINE 4 ON HISTONE H3 (H3K4ME3) AT TRPV1 PROMOTERS, THUS RESULTING IN TRPV1 TRANSCRIPTIONAL ACTIVATION (MD: 0.65, 95% CI, 0.82-0.49; P < .001 FOR VEHICLE) IN DRG IN PTX-INDUCED NEUROPATHIC PAIN. MOREOVER, PTX INCREASED THE ACTIVITY OF NADPH OXIDASE 4 (NOX4) (MD: 0.66, 95% CI, 0.81-0.51; P < .001 FOR VEHICLE), PRMT5-INDUCED H3R2ME2S, AND WDR5-MEDIATED H3K4ME3 IN THE DRG IN PTX-INDUCED NEUROPATHIC PAIN. PHARMACOLOGICAL ANTAGONISM AND THE SELECTIVE KNOCKDOWN OF PRMT5 IN DRG NEURONS COMPLETELY BLOCKED PRMT5-MEDIATED H3R2ME2S, WDR5-MEDIATED H3K4ME3, OR TRPV1 EXPRESSION AND NEUROPATHIC PAIN DEVELOPMENT AFTER PTX INJECTION. REMARKABLY, NOX4 INHIBITION NOT ONLY ATTENUATED ALLODYNIA BEHAVIOR AND REVERSED THE ABOVE-MENTIONED SIGNALING BUT ALSO REVERSED NOX4 UPREGULATION VIA PTX. CONCLUSIONS: THUS, THE NOX4/PRMT5-ASSOCIATED EPIGENETIC MECHANISM IN DRG HAS A DOMINANT FUNCTION IN THE TRANSCRIPTIONAL ACTIVATION OF TRPV1 IN PTX-INDUCED NEUROPATHIC PAIN. 2023 2 5062 77 PHOSPHATE NIMA-RELATED KINASE 2-DEPENDENT EPIGENETIC PATHWAYS IN DORSAL ROOT GANGLION NEURONS MEDIATES PACLITAXEL-INDUCED NEUROPATHIC PAIN. BACKGROUND: THE MICROTUBULE-STABILIZING DRUG PACLITAXEL (PTX) IS AN IMPORTANT CHEMOTHERAPEUTIC AGENT FOR CANCER TREATMENT AND CAUSES PERIPHERAL NEUROPATHY AS A COMMON SIDE EFFECT THAT SUBSTANTIALLY IMPACTS THE FUNCTIONAL STATUS AND QUALITY OF LIFE OF PATIENTS. THE MECHANISTIC ROLE FOR NIMA-RELATED KINASE 2 (NEK2) IN THE PROGRESSION OF PTX-INDUCED NEUROPATHIC PAIN HAS NOT BEEN ESTABLISHED. METHODS: ADULT MALE SPRAGUE-DAWLEY RATS INTRAPERITONEALLY RECEIVED PTX TO INDUCE NEUROPATHIC PAIN. THE PROTEIN EXPRESSION LEVELS IN THE DORSAL ROOT GANGLION (DRG) OF ANIMALS WERE MEASURED BY BIOCHEMICAL ANALYSES. NOCICEPTIVE BEHAVIORS WERE EVALUATED BY VON FREY TESTS AND HOT PLATE TESTS. RESULTS: PTX INCREASED PHOSPHORYLATION OF THE IMPORTANT MICROTUBULE DYNAMICS REGULATOR NEK2 IN DRG NEURONS AND INDUCED PROFOUND NEUROPATHIC ALLODYNIA. PTX-ACTIVATED PHOSPHORYLATED NEK2 (PNEK2) INCREASED JUMONJI DOMAIN-CONTAINING 3 (JMJD3) PROTEIN, A HISTONE DEMETHYLASE PROTEIN, TO SPECIFICALLY CATALYZE THE DEMETHYLATION OF THE REPRESSIVE HISTONE MARK H3 LYSINE 27 TRIMETHYLATION (H3K27ME3) AT THE TRPV1 GENE, THEREBY ENHANCING TRANSIENT RECEPTOR POTENTIAL VANILLOID SUBTYPE-1 (TRPV1) EXPRESSION IN DRG NEURONS. MOREOVER, THE PNEK2-DEPENDENT PTX RESPONSE PROGRAM IS REGULATED BY ENHANCING P90 RIBOSOMAL S6 KINASE 2 (RSK2) PHOSPHORYLATION. CONVERSELY, INTRATHECAL INJECTIONS OF KAEMPFEROL (A SELECTIVE RSK2 ACTIVATION ANTAGONIST), NCL 00017509 (A SELECTIVE NEK2 INHIBITOR), NEK2-TARGETED SIRNA, GSK-J4 (A SELECTIVE JMJD3 INHIBITOR), OR CAPSAZEPINE (AN ANTAGONIST OF TRPV1 RECEPTOR) INTO PTX-TREATED RATS REVERSED NEUROPATHIC ALLODYNIA AND RESTORED SILENCING OF THE TRPV1 GENE, SUGGESTING THE HIERARCHY AND INTERACTION AMONG PHOSPHORYLATED RSK2 (PRSK2), PNEK2, JMJD3, H3K27ME3, AND TRPV1 IN THE DRG NEURONS IN PTX-INDUCED NEUROPATHIC PAIN. CONCLUSIONS: PRSK2/JMJD3/H3K27ME3/TRPV1 SIGNALING IN THE DRG NEURONS PLAYS AS A KEY REGULATOR FOR PTX THERAPEUTIC APPROACHES. 2023 3 743 40 CANNABINOID TYPE 2 RECEPTOR SYSTEM MODULATES PACLITAXEL-INDUCED MICROGLIAL DYSREGULATION AND CENTRAL SENSITIZATION IN RATS. PACLITAXEL INDUCES MICROGLIAL ACTIVATION AND PRODUCTION OF PROINFLAMMATORY MEDIATORS IN THE DORSAL HORN, WHICH CONTRIBUTE TO THE DEVELOPMENT AND MAINTENANCE OF CENTRAL SENSITIZATION AND PAIN BEHAVIOR. MDA7, 1-([3-BENZYL-3-METHYL-2,3-DIHYDRO-1-BENZOFURAN-6-YL]CARBONYL) PIPERIDINE, IS A NOVEL HIGHLY SELECTIVE CANNABINOID TYPE 2 (CB2) AGONIST. WE TESTED THE HYPOTHESIS THAT ACTIVATION OF CB2 RECEPTOR BY MDA7 MODULATES MICROGLIAL DYSREGULATION, SUPPRESSES THE OVEREXPRESSION OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IN MICROGLIA IN THE DORSAL HORN, AND ATTENUATES THE CENTRAL SENSITIZATION AND PAIN BEHAVIOR INDUCED BY PACLITAXEL. FOR 4 CONSECUTICE DAYS, GROUPS OF RATS RANDOMLY RECEIVED SALINE OR 1.0 MG/KG OF PACLITAXEL DAILY INTRAPERITONEALLY FOR A TOTAL CUMULATIVE DOSE OF 4 MG/KG. MDA7 15 MG/KG INTRAPERITONEALLY OR VEHICLE WERE ADMINISTERED 15 MIN BEFORE ADMINISTERING PACLITAXEL FOR 4 DAYS AND THEN CONTINUED FOR ANOTHER 10 DAYS. BEHAVIORAL AND MOLECULAR STUDIES WERE PERFORMED. PACLITAXEL INDUCED THE EXPRESSION OF CB2 RECEPTORS AND PRODUCTION OF INTERLEUKIN (IL)-6 IN MICROGLIA IN THE DORSAL HORN. MDA7 ATTENUATED THE EXPRESSION OF IL-6 AND PROMOTED THE EXPRESSION OF IL-10. PACLITAXEL INDUCED EPIGENETIC UPREGULATION OF IRF8 AND P2X PURINOCEPTOR 4 (P2X4) IN MICROGLIA AND SUBSEQUENTLY INCREASED THE EXPRESSION OF ALPHA ISOFORM OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II (CAMKIIALPHA), TRANSCRIPTIONAL FACTORS P-CREB AND DELTAFOSB, LEADING TO THE OVERPRODUCTION OF BDNF IN MICROGLIA. PACLITAXEL ALSO UPREGULATED THE EXPRESSION OF GLUTAMATE RECEPTOR SUBUNITS GLUR1 AND NR2B, DECREASED THE EXPRESSION OF K(+)-CL(-) COTRANSPORTER, AND INDUCED MECHANICAL ALLODYNIA IN RATS. ALL OF THE AFOREMENTIONED MOLECULAR CHANGES WERE ATTENUATED BY MDA7. OUR DATA SHOW THAT MDA7 ATTENUATED PACLITAXEL-INDUCED MOLECULAR AND BEHAVIORAL CHANGES IN RATS. PERSPECTIVE: THIS STUDY PROVIDES EVIDENCE THAT PACLITAXEL INDUCED MICROGLIA DYSREGULATION AND EPIGENETICALLY UPREGULATED THE MICROGLIAL EXPRESSION OF BDNF, WHICH LED TO SENSITIZATION OF DORSAL HORN NEURONS AND MECHANICAL ALLODYNIA IN RATS. THE CB2 AGONIST MDA7 ALLEVIATED THESE PATHOLOGICAL PROCESSES. MDA7 REPRESENTS AN INNOVATIVE THERAPEUTIC APPROACH FOR TREATMENT OF CHEMOTHERAPY-INDUCED NEUROPATHY. 2019 4 5401 52 REDUCTION OF SIRT1 EPIGENETICALLY UPREGULATES NALP1 EXPRESSION AND CONTRIBUTES TO NEUROPATHIC PAIN INDUCED BY CHEMOTHERAPEUTIC DRUG BORTEZOMIB. BACKGROUND: BORTEZOMIB IS A FREQUENTLY USED CHEMOTHERAPEUTIC DRUG FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER NONSOLID MALIGNANCIES. ACCUMULATING EVIDENCE HAS DEMONSTRATED THAT BORTEZOMIB-INDUCED PERSISTENT PAIN SERVES AS THE MOST FREQUENT REASON FOR TREATMENT DISCONTINUATION. METHODS: THE VON FREY TEST WAS PERFORMED TO EVALUATE NEUROPATHIC PAIN BEHAVIOR, AND REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, CHROMATIN IMMUNOPRECIPITATION, WESTERN BLOT, IMMUNOHISTOCHEMISTRY, AND SMALL INTERFERING RNA WERE PERFORMED TO EXPLORE THE MOLECULAR MECHANISMS IN ADULT MALE SPRAGUE-DAWLEY RATS. RESULTS: WE FOUND THAT APPLICATION OF BORTEZOMIB SIGNIFICANTLY INCREASED THE EXPRESSION OF NALP1 PROTEIN AND MRNA LEVELS IN SPINAL DORSAL HORN NEURONS, AND INTRATHECAL APPLICATION OF NALP1 SIRNA ATTENUATED THE BORTEZOMIB-INDUCED MECHANICAL ALLODYNIA. IN ADDITION, BORTEZOMIB ALSO DECREASED THE SIRT1 EXPRESSION, AND TREATMENT WITH SIRT1 ACTIVATOR RESVERATROL AMELIORATED THE NALP1 UPREGULATION AND MECHANICAL ALLODYNIA INDUCED BY BORTEZOMIB. MEANWHILE, KNOCKDOWN OF SIRT1 USING THE SIRT1 SIRNA INDUCED THE NALP1 UPREGULATION IN DORSAL HORN AND MECHANICAL ALLODYNIA IN NORMAL ANIMAL. THESE RESULTS SUGGESTED THAT REDUCTION OF SIRT1 INDUCED THE NALP1 UPREGULATION IN DORSAL HORN NEURONS, AND PARTICIPATED IN BORTEZOMIB-INDUCED MECHANICAL ALLODYNIA. IMPORTANTLY, WE FOUND THAT THE BINDING OF SIRT1 AND NALP1 PROMOTER REGION DID NOT CHANGE BEFORE AND AFTER BORTEZOMIB TREATMENT, BUT SIRT1 DOWNREGULATION INCREASED P-STAT3 EXPRESSION. FURTHERMORE, THE ACTIVATION OF STAT3 ENHANCED THE RECRUITMENT OF P-STAT3 TO THE NALP1 GENE PROMOTER, WHICH INCREASED THE ACETYLATION OF HISTONE H3 AND H4 IN NALP1 PROMOTER REGIONS AND EPIGENETICALLY UPREGULATED NALP1 EXPRESSION IN THE RODENTS WITH BORTEZOMIB TREATMENT. CONCLUSION: THESE FINDINGS SUGGESTED A NEW EPIGENETIC MECHANISM FOR NALP1 UPREGULATION INVOLVING SIRT1 REDUCTION AND SUBSEQUENT STAT3-MEDIATED HISTONE HYPERACETYLATION IN NALP1 PROMOTER REGION IN DORSAL HORN NEURONS, WHICH CONTRIBUTED TO THE BORTEZOMIB-INDUCED MECHANICAL ALLODYNIA. 2018 5 6148 46 THE EXPRESSION OF TRANSCRIPTION FACTORS MECP2 AND CREB IS MODULATED IN INFLAMMATORY PELVIC PAIN. EARLY ACTIVATION OF TRANSCRIPTION FACTORS IS ONE OF THE EPIGENETIC MECHANISMS CONTRIBUTING TO THE INDUCTION AND MAINTENANCE OF CHRONIC PAIN STATES. PREVIOUS STUDIES IDENTIFIED THE CHANGES IN A NUMBER OF NOCICEPTION-RELATED GENES, SUCH AS CALCITONIN GENE-RELATED PEPTIDE (CGRP), SUBSTANCE P (SP), AND BRAIN-DERIVED NEUROTROPIC FACTOR (BDNF) IN THE PELVIC ORGANS AFTER TRANSIENT COLONIC INFLAMMATION. THE GENE AND PROTEIN EXPRESSION OF THESE NEUROPEPTIDES COULD BE MODULATED BY TRANSCRIPTION FACTORS METHYL-CPG-BINDING PROTEIN 2 (MECP2) AND CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB). IN THIS STUDY, WE AIMED TO EVALUATE TIME-DEPENDENT CHANGES IN THE EXPRESSION LEVELS OF MECP2 AND CREB IN THE LUMBOSACRAL (LS) SPINAL CORD AND SENSORY GANGLIA AFTER INFLAMMATION-INDUCED PELVIC PAIN IN RAT. ADULT SPRAGUE-DAWLEY RATS WERE TREATED WITH 2,4,6-TRINITROBENZENESULFONIC ACID (TNBS) TO INDUCE TRANSIENT COLONIC INFLAMMATION. LS (L6-S2) SPINAL CORD SEGMENTS AND RESPECTIVE DORSAL ROOT GANGLIAS (DRGS) WERE ISOLATED FROM CONTROL AND EXPERIMENTAL ANIMALS AT 1, 2, 6, 24 H AND 3 DAYS POST-TNBS TREATMENT. IMMUNOHISTOCHEMICAL (IHC) LABELING AND WESTERN BLOTTING EXPERIMENTS WERE PERFORMED TO ASSESS THE EXPRESSION OF MECP2, CREB AND THEIR PHOSPHORYLATED FORMS. TOTAL MECP2 EXPRESSION, BUT NOT PHOSPHORYLATED P-MECP2 (PS421MECP2) EXPRESSION WAS DETECTED IN THE CELLS OF THE SPINAL DORSAL HORN UNDER CONTROL CONDITIONS. COLONIC INFLAMMATION TRIGGERED A SIGNIFICANT DECREASE IN THE NUMBER OF MECP2-EXPRESSING NEURONS IN PARALLEL WITH ELEVATED NUMBERS OF PS421MECP2-EXPRESSING CELLS AT 2 H AND 6 H POST-TNBS. THE MAJORITY OF MECP2-POSITIVE CELLS (80 +/- 6%) CO-EXPRESSED CREB. TNBS TREATMENT CAUSED A TRANSIENT UP-REGULATION OF CREB-EXPRESSING CELLS AT 1 H POST-TNBS ONLY. THE NUMBER OF CELLS EXPRESSING PHOSPHORYLATED CREB (PS133CREB) DID NOT CHANGE AT 1 H AND 2 H POST-TNBS, BUT WAS DOWN-REGULATED BY THREE FOLDS AT 6 H POST-TNBS. ANALYSIS OF DRG SECTIONS REVEALED THAT THE NUMBER OF MECP2-POSITIVE NEURONS WAS UP-REGULATED BY TNBS TREATMENT, REACHING THREE-FOLD INCREASE AT 2 H POST-TNBS, AND EIGHT-FOLD INCREASE AT 6 H POST-TNBS (P